Antares Pharma, Inc.
100 Princeton South, Suite 300
Ewing, NJ 08628
May 16, 2017
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Amanda Ravitz, Assistant Director, Office of Electronics and Machinery | |
Caleb French |
Re: | Antares Pharma, Inc. | |
Registration Statement on Form S-3 | ||
Filed May 9, 2017 | ||
File No. 333-217808 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Antares Pharma, Inc. (the Company), hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-217808), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on May 18, 2017, or as soon as practicable thereafter.
ANTARES PHARMA, INC. | ||
By: | /s/ Fred M. Powell | |
Name: | Fred M. Powell | |
Title: | Senior Vice President and Chief Financial Officer |